CRIS Current Research Information System

GRAMANTIERI, LAURA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.396
EU - Europa 2.018
AS - Asia 910
AF - Africa 107
SA - Sud America 25
Continente sconosciuto - Info sul continente non disponibili 16
Totale 5.472
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.382
IT - Italia 449
GB - Regno Unito 382
CN - Cina 345
SG - Singapore 312
SE - Svezia 251
DE - Germania 233
NL - Olanda 126
RU - Federazione Russa 111
IN - India 106
IE - Irlanda 86
CH - Svizzera 78
FR - Francia 78
UA - Ucraina 58
VN - Vietnam 48
BG - Bulgaria 41
TG - Togo 40
FI - Finlandia 34
ZA - Sudafrica 32
EE - Estonia 28
ID - Indonesia 23
JO - Giordania 21
CI - Costa d'Avorio 17
EU - Europa 15
EC - Ecuador 13
BR - Brasile 11
CA - Canada 11
HK - Hong Kong 11
BE - Belgio 10
KR - Corea 10
HR - Croazia 9
MK - Macedonia 9
AT - Austria 8
JP - Giappone 7
NG - Nigeria 6
PK - Pakistan 6
IL - Israele 5
PL - Polonia 5
CZ - Repubblica Ceca 4
DZ - Algeria 4
RO - Romania 4
SC - Seychelles 4
AM - Armenia 3
GR - Grecia 3
LB - Libano 3
LT - Lituania 3
DK - Danimarca 2
ES - Italia 2
KZ - Kazakistan 2
MD - Moldavia 2
MX - Messico 2
SI - Slovenia 2
TN - Tunisia 2
TR - Turchia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BD - Bangladesh 1
CU - Cuba 1
EG - Egitto 1
IR - Iran 1
KE - Kenya 1
LK - Sri Lanka 1
MY - Malesia 1
PE - Perù 1
TH - Thailandia 1
UZ - Uzbekistan 1
Totale 5.472
Salva come PNG Salva come JPEG
Città #
Southend 349
Fairfield 302
Singapore 254
Chandler 214
Ashburn 193
Woodbridge 159
Santa Clara 150
Houston 141
Bologna 132
Wilmington 129
Seattle 127
Princeton 88
Dublin 86
Ann Arbor 79
Cambridge 79
Bern 75
Boardman 72
Sofia 41
Lomé 40
Dong Ket 35
Jacksonville 34
Westminster 34
Nanjing 32
Padova 32
Helsinki 29
Milan 27
Beijing 25
Berlin 23
Amman 21
Jakarta 21
Saint Petersburg 19
Jinan 18
New York 18
Abidjan 17
Hebei 17
San Diego 17
Turin 16
Zhengzhou 16
Florence 15
Düsseldorf 14
Los Angeles 12
Amsterdam 11
Hong Kong 11
Nanchang 11
Nuremberg 11
Shanghai 11
Brussels 10
Des Moines 10
Jiaxing 10
Pune 10
Seoul 10
Shenyang 10
Bremen 9
Guangzhou 9
Bühl 8
Changsha 8
Dearborn 8
Falls Church 8
Forlì 8
Haikou 8
Lauterbourg 8
Medford 8
Mülheim 8
Norwalk 8
Quito 8
Rome 8
Falkenstein 7
Frankfurt am Main 7
Yubileyny 7
Abeokuta 6
Chicago 6
Council Bluffs 6
Moscow 6
Munich 6
San Giorgio di Piano 6
Skopje 6
Taizhou 6
Toronto 6
Guayaquil 5
Holon 5
Mountain View 5
Ningbo 5
Phoenix 5
Shenzhen 5
Tianjin 5
Verona 5
Wuhan 5
Ōtsu 5
Chengdu 4
London 4
Medolla 4
Olalla 4
Philadelphia 4
Reggio Nell'emilia 4
Suzhou 4
Taiyuan 4
Treviso 4
Vienna 4
Bari 3
Bolzano 3
Totale 3.602
Salva come PNG Salva come JPEG
Nome #
Circulating microRNAs, MIR-939, MIR-595, MIR-519d and MIR-494, identify cirrhotic patients with HCC 212
LncRNAs as novel players in hepatocellular carcinoma recurrence 155
Corrigendum: Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma (Scientific Reports (2017) 7 (44685) DOI: 10.1038/srep44685) 150
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. 144
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 142
MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer 142
Venom from Cuban Blue Scorpion has tumor activating effect in hepatocellular carcinoma 136
F.N.27 NOTCH SIGNALLING CONTROLS PROLIFERATION AND SENESCENCE OF HUMAN HEPATOCELLULAR CARCINOMA 135
Oncogenic role of miR-483-3p at the IGF2/483 locus. 131
Molecular and proteomic insight into Notch1 characterization in hepatocellular carcinoma 131
MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma 131
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. 130
Targeting notch3 in hepatocellular carcinoma: Molecular mechanisms and therapeutic perspectives 127
Direct antiviral treatments for hepatitis c virus have off-target effects of oncologic relevance in hepatocellular carcinoma 122
MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma 121
MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. 119
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. 116
GADD45alpha expression in cirrhosis and hepatocellular carcinoma. Relationship with DNA-repair and proliferation. 116
Different haemodynamic effects of a single dose of long-acting isosorbide-5-mononitrate in healthy subjects and patients with cirrhotic portal hypertension. 113
Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas 113
Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. 110
p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma 110
Role of SIRT-3, p-mTOR and HIF-1α in Hepatocellular Carcinoma Patients Affected by Metabolic Dysfunctions and in Chronic Treatment with Metformin 109
MicroRNAs in Animal Models of HCC 109
Improving accuracy in the diagnosis of small HCC (< 20 mm) on cirrhosis by a combined CT-MRI Ultrasound navigation system. Preliminary report of a work in progress. 108
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 107
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. 107
Frequent aberrant methylation of the CDH4 gene promoter in human colorectal and gastric cancer. 103
Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area 101
TP53/MicroRNA interplay in hepatocellular carcinoma 101
T.N.28 P53 IS REGULATED BY NOTCH3 SIGNALLING VIA MDM2 IN HEPATOCELLULAR CARCINOMA 100
Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma 95
Hepatic cancer stem cells: Molecular mechanisms, therapeutic implications, and circulating biomarkers 90
Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions 89
Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. 88
MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches 88
Correction to: Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma (Targeted Oncology, (2020), 15, 6, (773-785), 10.1007/s11523-020-00757-3) 87
Notch3 inhibition enhances sorafenib cytotoxic efficacy by promoting GSK3b phosphorylation and p21 down-regulation in hepatocellular carcinoma. 85
Efficacy of superselective TACE in treatment of HCC 82
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 81
Notch3 intracellular domain accumulates in HepG2 cell line. 77
null 77
Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma 73
c-MET receptor tyrosine kinase as a molecular target in advanced hepatocellular carcinoma 71
MiR-122 targets serpinB3 and is involved in sorafenib resistance in hepatocellular carcinoma 67
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma 66
MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma 59
MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma 58
Notch signaling regulation in HCC: From hepatitis virus to non‐coding rnas 54
Animal Models of Hepatocellular Carcinoma: Current Applications in Clinical Research 50
Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response 49
Emerging role of microRNAs in the treatment of hepatocellular carcinoma 44
Animal models of hepatocellular carcinoma prevention 43
miRNA Signature of Hepatocellular Carcinoma Vascularization: How the Controls Can Influence the Signature 42
Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma 38
Notch Signaling and PD-1/PD-L1 Interaction in Hepatocellular Carcinoma: Potentialities of Combined Therapies 31
MicroRNA as predictive biomarkers of treatment response to tyrosine kinase inhibitors in hepatocellular carcinoma: how much is missing? 31
Brivanib in combination with Notch3 silencing shows potent activity in tumour models 28
Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab–bevacizumab resistance and worse survival in advanced hepatocarcinoma 27
Laboratory signs of acute or recent cytomegalovirus infection are common in cirrhosis of the liver 24
Multifaceted Aspects of Dysfunctional Myelopoiesis in Cancer and Therapeutic Perspectives with Focus on HCC 19
Pathophysiology roles and translational opportunities of miRNAs in hepatocellular carcinoma 19
Totale 5.683
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.894
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.894
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202098 0 0 0 0 0 0 0 0 0 0 50 48
2020/2021558 109 42 16 15 11 38 43 40 75 47 24 98
2021/2022976 55 44 60 86 74 47 19 96 36 84 253 122
2022/20231.084 99 121 62 123 65 93 21 57 192 28 76 147
2023/2024411 32 70 19 37 55 79 13 20 19 30 13 24
2024/20251.262 87 222 141 116 214 55 121 45 44 181 36 0
Totale 5.683